Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer

Oncology

Volumn 64, Issue 2, 2003, Pages 124-130

  Aihara, Tomohiko ^a   Takatsuka, Yuichi ^a   Itoh, Kuniaki ^b   Sasaki, Yasutsuna ^b   Katsumata, Noriyuki ^c   Watanabe, Toru ^c   Noguchi, Shinzaburo ^d   Horikoshi, Noboru ^e   Tabei, Toshio ^f   Sonoo, Hiroshi ^g   Hiraki, Shunkichi ^h   Inaji, Hideo ⁱ  

^a KANSAI ROSAI HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^e CANCER INSTITUTE HOSPITAL   (Japan)

^f SAITAMA CANCER CENTER   (Japan)

^g KAWASAKI MEDICAL SCHOOL   (Japan)

^h Japanese Red Cross Okayama Hospital   (Japan)

ⁱ OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Breast cancer; Chemotherapy; Docetaxel; Doxorubicin; Phase II study

Indexed keywords

DOCETAXEL; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; ASTHENIA; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DUODENUM ULCER; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLUSHING; GASTROINTESTINAL DISEASE; HUMAN; HYPERSENSITIVITY; INFECTION; LIVER DISEASE; NAIL DISEASE; NEUROTOXICITY; PRIORITY JOURNAL; SIDE EFFECT; SKIN DISEASE; STOMATITIS; TASTE DISORDER; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; TAXOIDS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0037259892     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067771     Document Type: Article

References (31)

1. Ellis MJ, Hayes DF, Lippman ME: Treatment of Metastatic Breast Cancer; in Harris JR, Lippman ME, Morrow M, Osborn CK (eds): Diseases of the Breast, ed 2. Philadelphia, Lippincott, 2000, pp 749-797.
2. A'Hern RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens. Br J Cancer 1993;67:801-805.
3. Delecroix V, Fumoleau P, Perrocheau G, Azli N, Féty R, Priou F, Maugard C, Riva A, Lemevel B: Anthracycline as second-line chemotherapy (CT) for metastatic breast cancer patients previously treated with Taxotere (TXT) (abstract 578). Proc Am Soc Clin Oncol 1997;16:166a.
4. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 1999;17:2341-2354.
5. Adachi I, Watanabe T, Takashima S, Narabayashi M, Horikoshi N, Aoyama H, Taguchi T: A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 1996;73:210-216.
6. ten Bokkel Huinink WW, Prove AM, Piccart M, Steward W, Tursz T, Wanders J, Franklin H, Clavel M, Verweij J, Alakl M, Bayssas M, Kaye SB: A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 1994;5:527-532.
7. Alexandre J, Bleuzen P, Bonneterre J, Sutherland W, Misset JL, Guastalla J, Viens P, Faivre S, Chahine A, Spielman M, Bensmaine A, Marty M, Mahjoubi M, Cvitkovic E: Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 2000;18:562-573.
8. Bonneterre J, Spielman M, Guastalla JP, Marty M, Viens P, Chollet P, Roche H, Fumoleau P, Mauriac L, Bourgeois H, Namer M, Bergerat JP, Misset JL, Trandafir L, Mahjoubi M: Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: The French compassionate use programme experience. Eur J Cancer 1999;35:1431-1439.
9. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995;13:314-322.
10. -2 as first-line chemotherapy for patients with advanced breast cancer: Report of the Clinical Screening Group of the EORTC. Br J Cancer 1996;74:650-656.
11. Fumoleau P, Chevallier B, Kerbrat P, Krakowski Y, Misset JL, Maugard-Louboutin C, Dieras V, Azli N, Bougon N, Riva A, Roche H: A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC. Ann Oncol 1996;7:165-171.
12. O'Brien ME, Leonard RC, Barrett-Lee PJ, Eggleton SP, Bizzari JP: Docetaxel in the community setting: An analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group. Ann Oncol 1999;10:205-210.
13. Ravdin PM, Burris HA, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE: Phase II of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879-2885.
14. Valero V, Holmes FA, Walter RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN: Phase II trial of docetaxel: A new, highly effective anti-neoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886-2894.
15. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999;17:1413-1424.
16. Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjovall M, Wist E, Valvere V, Anderson H, Bergh J: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scand Breast Group. Eur J Cancer 1999;35:1194-1201.
17. Misset JL, Dieras V, Gruia G, Bourgeois H, Cvitkovic E, Kalla S, Bozec L, Beuzeboc P, Jasmin C, Aussel JP, Riva A, Azli N, Pouillart P: Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 1999;10:553-560.
18. Itoh K, Sasaki Y, Fujii H, Minami H, Ohtsu T, Wakita H, Igarashi T, Watanabe Y, Onozawa Y, Kashimura M, Ohashi Y: Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer. Clin Cancer Res 2000;6:4082-4090.
19. Japanese Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer (in Japanese), ed 12. Tokyo, Kanabara Shuppan, 1992, pp 53-61.
20. Gehl J, Boesgaard M, Paaske T, Vittrup Jensen B, Dombernowsky P: Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic. Ann Oncol 1996;7:687-693.
21. Sparano JA, Hu P, Rao RM, Falkson CI, Wolff AC, Wood WC: Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: An Eastern Cooperative Oncology Group Study. J Clin Oncol 1999;17:3828-3834.
22. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995;13:2688-2699.
23. Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E, Bonadonna G: Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 1997;15:1906-1915.
24. D'Incalci M, Schuller J, Colombo T, Zucchetti M, Riva A: Taxoids in combination with anthracyclines and other agents: Pharmacokinetic considerations. Semin Oncol 1998;25:16-20.
25. Bellot R, Robert J, Dieras V, Misset JL, Baille P, Bozec L, Vernillet L, Riva A, Azli N, Pouillart P: Taxotere does not change the pharmacokinetic profile of doxorubicin and doxorubicinol (abstract 853). Proc Am Soc Clin Oncol 1998;17:221a.
26. Dieras V, Barthier S, Beuzeboc P, Misset JL, Cottura E, Aussel JP, Delaloge S, Jouve M, Riva A, Azli N, Pouillart P: Phase II study of taxotere in combination with doxorubicin as 1st line chemotherapy of metastatic breast cancer (abstract 226). Breast Cancer Res Treat 1998;50:262a.
27. Sparano JA, O'Neill A, Schaefer PL, Falkson CI, Wood WC: Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J Clin Oncol 2000;18:2369-2377.
28. Nabholtz JM, Mackey JR, Smylie M, Paterson A, Noel DR, Al-Tweigeri T, Tonkin K, North S, Azli N, Riva A: Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 2001;19:314-321.
29. Nabholtz JM, Falkson G, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Bezwoda WR, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P: A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC (abstract 485). Proc Am Soc Clin Oncol 1999;18:127a.
30. Nabholtz JM, Paterson A, Dirix JL, Dewar J, Chap L, Martin M, Chan S, Tang SC, Dugan W, Gil M, Zaluski J, Russel C, Vogel C, Borg-Olivier O, Riva A, Murawsky M, Azli N, Efremidis A: A phase III randomized trial comparing docetaxel, doxorubicin and cyclophosphamide (TAC) to FAC as first line chemotherapy for patients with metastatic breast cancer (abstract 83). Proc Am Soc Clin Oncol 2001;20:21a.
31. Khayat D, Chollet P, Antoine EC, Monfardini S, Ambrosini G, Benhammouda A, Mazen MF, Sorio R, Borg-Olivier O, Riva A, Ramazeilles C, Azli N: Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 2001;19:3367-3375.